{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:40:43Z","timestamp":1790703643807,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer is a leading cause of male cancer-related deaths over the age of 50. New treatment options are urgently needed, especially for prostate tumours that have spread to bone. Targeting aberrant sialylation holds substantial potential for the development of new therapeutics but is relatively unexplored in the context of prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, using high-affinity Siglec-based sialoglycan-binding reagents (HYDRA) for immunohistochemistry, we quantify tumour sialoglycans in tissues representing the full clinical heterogeneity of prostate cancer. Using immunofluorescence, we profile Siglec receptors in prostate tumours, and using syngeneic mouse models, we evaluate an engineered dual-action sialidase (E-612) as a treatment for prostate cancer bone metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We find that sialoglycans that can engage Siglec-3 (CD33), Siglec-7 and Siglec-9 are upregulated in bone metastatic prostate cancer and show that sialoglycan ligands for Siglec-7 and -9 correlate with poorer patient prognosis. Furthermore, we reveal Siglec receptors and Siglec ligands are co-expressed by immune cells in prostate-derived tumours growing in bone. Indicating the Siglec-sialoglycan axis is clinically actionable in prostate cancer, we show systemic therapy with E-612 can suppress the growth of tumours, increase immune cell infiltration and prolong survival times of mice with bone metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identify a novel mechanism involving Siglec-engaging sialoglycans in driving the growth of prostate cancer bone metastasis and demonstrate that targeting this axis using an engineered sialidase can impede lethal prostate cancer progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03544-5","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:21:17Z","timestamp":1783923677000},"page":"1164-1177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis"],"prefix":"10.1038","volume":"135","author":[{"given":"Ziqian","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-0430","authenticated-orcid":false,"given":"Kirsty","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Orozco-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Gatlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Donald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libby","family":"Blencoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feier","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-923X","authenticated-orcid":false,"given":"Michelle A.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-932X","authenticated-orcid":false,"given":"Richard","family":"Beatson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-4531","authenticated-orcid":false,"given":"Jennifer","family":"Munkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"3544_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3544_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/ol.2023.13749","volume":"25","author":"GE Archer","year":"2023","unstructured":"Archer GE, Wang N, Munkley J. Prostate cancer bone metastases biology and clinical management (Review). Oncol Lett. 2023;25:163.","journal-title":"Oncol Lett"},{"key":"3544_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88\u201399.","journal-title":"Eur Urol"},{"key":"3544_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.eururo.2018.07.035","volume":"75","author":"J Mateo","year":"2019","unstructured":"Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen W, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75:285\u201393.","journal-title":"Eur Urol"},{"key":"3544_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3934\/molsci.2016.2.280","volume":"3","author":"EL Karen","year":"2016","unstructured":"Karen EL, Jennifer M, David JE. Androgen receptor and prostate cancer. AIMS Mol Sci. 2016;3:280\u201399.","journal-title":"AIMS Mol Sci"},{"key":"3544_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5489\/cuaj.10167","volume":"4","author":"F Saad","year":"2010","unstructured":"Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4:380\u20134.","journal-title":"Can Urol Assoc J"},{"key":"3544_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-10-23","volume":"10","author":"C Nieder","year":"2010","unstructured":"Nieder C, Haukland E, Pawinski A, Dalhaug A. Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. BMC Urol. 2010;10:23.","journal-title":"BMC Urol"},{"key":"3544_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355.","journal-title":"Nat Rev Cancer"},{"key":"3544_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.trecan.2020.04.002","volume":"6","author":"AF Costa","year":"2020","unstructured":"Costa AF, Campos D, Reis CA, Gomes C. Targeting glycosylation: a new road for cancer drug discovery. Trends Cancer. 2020;6:757\u201366.","journal-title":"Trends Cancer"},{"key":"3544_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/glycob\/cww086","volume":"27","author":"A Varki","year":"2017","unstructured":"Varki A. Biological roles of glycans. Glycobiology. 2017;27:3\u201349.","journal-title":"Glycobiology"},{"key":"3544_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nri.2018.3","volume":"18","author":"E RodrIguez","year":"2018","unstructured":"RodrIguez E, Schetters STT, van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018;18:204\u201311.","journal-title":"Nat Rev Immunol"},{"key":"3544_CR12","doi-asserted-by":"publisher","first-page":"35478","DOI":"10.18632\/oncotarget.8155","volume":"7","author":"J Munkley","year":"2016","unstructured":"Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget. 2016;7:35478\u201389.","journal-title":"Oncotarget"},{"key":"3544_CR13","doi-asserted-by":"crossref","unstructured":"Munkley J. Aberrant sialylation in cancer: therapeutic opportunities. Cancers. 2022;14:4248.","DOI":"10.3390\/cancers14174248"},{"key":"3544_CR14","doi-asserted-by":"publisher","first-page":"110641","DOI":"10.1016\/j.jbc.2025.110641","volume":"301","author":"SJ van Vliet","year":"2025","unstructured":"van Vliet SJ, van Kooyk Y. Sialic acids in cancer biology and immunity- recent advancements. J Biol Chem. 2025;301:110641.","journal-title":"J Biol Chem"},{"key":"3544_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-020-01126-7","volume":"124","author":"C Dobie","year":"2021","unstructured":"Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 2021;124:76\u201390.","journal-title":"Br J Cancer"},{"key":"3544_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41573-020-00093-1","volume":"20","author":"BAH Smith","year":"2021","unstructured":"Smith BAH, Bertozzi CR. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. Nat Rev Drug Discov. 2021;20:217\u201343.","journal-title":"Nat Rev Drug Discov"},{"key":"3544_CR17","doi-asserted-by":"publisher","first-page":"22982","DOI":"10.1074\/jbc.M110.211375","volume":"286","author":"AF Swindall","year":"2011","unstructured":"Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem. 2011;286:22982\u201390.","journal-title":"J Biol Chem"},{"key":"3544_CR18","doi-asserted-by":"publisher","first-page":"108043","DOI":"10.1016\/j.jbc.2024.108043","volume":"301","author":"J Hwang","year":"2025","unstructured":"Hwang J, Rao TC, Tao J, Sha B, Narimatsu Y, Clausen H, et al. Apoptotic signaling by TNFR1 is inhibited by the \u03b12-6 sialylation, but not \u03b12-3 sialylation, of the TNFR1 N-glycans. J Biol Chem. 2025;301:108043.","journal-title":"J Biol Chem"},{"key":"3544_CR19","doi-asserted-by":"publisher","first-page":"101726","DOI":"10.1016\/j.jbc.2022.101726","volume":"298","author":"TC Rao","year":"2022","unstructured":"Rao TC, Beggs RR, Ankenbauer KE, Hwang J, Ma VP, Salaita K, et al. ST6Gal-I-mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion. J Biol Chem. 2022;298:101726.","journal-title":"J Biol Chem"},{"key":"3544_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s13258-023-01445-y","volume":"45","author":"Y Luo","year":"2023","unstructured":"Luo Y, Cao H, Lei C, Liu J. ST6GALNAC1 promotes the invasion and migration of breast cancer cells via the EMT pathway. Genes Genom. 2023;45:1367\u201376.","journal-title":"Genes Genom"},{"key":"3544_CR21","doi-asserted-by":"crossref","unstructured":"Bull C, Nason R, Sun L, Van Coillie J, Madriz Sorensen D, Moons SJ, et al. Probing the binding specificities of human Siglecs by cell-based glycan arrays. Proc Natl Acad Sci USA. 2021;118:e2026102118.","DOI":"10.1073\/pnas.2026102118"},{"key":"3544_CR22","doi-asserted-by":"publisher","first-page":"104203","DOI":"10.1016\/j.labinv.2025.104203","volume":"105","author":"JR Ellis","year":"2025","unstructured":"Ellis JR, Will E, Ogurtsova A, Engle LL, Taube JM, Sunshine JC. Siglec ligand immunohistochemistry reveals association with immune exclusion and survival. Lab Invest. 2025;105:104203.","journal-title":"Lab Invest"},{"key":"3544_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nrurol.2016.65","volume":"13","author":"J Munkley","year":"2016","unstructured":"Munkley J, Mills IG, Elliott DJ. The role of glycans in the development and progression of prostate cancer. Nat Rev Urol. 2016;13:324\u201333.","journal-title":"Nat Rev Urol"},{"key":"3544_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ebiom.2016.04.018","volume":"8","author":"J Munkley","year":"2016","unstructured":"Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, et al. Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine. 2016;8:103\u201316.","journal-title":"EBioMedicine"},{"key":"3544_CR25","doi-asserted-by":"crossref","unstructured":"Hodgson K, Orozco-Moreno M, Peng Z, Blencoe L, Sharp MJ, Smith E, et al. The glycobiology of prostate cancer: an update. Oncogene. 2026;45:2655\u201370.","DOI":"10.1038\/s41388-026-03858-x"},{"key":"3544_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/path.6152","volume":"261","author":"E Scott","year":"2023","unstructured":"Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, et al. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. J Pathol. 2023;261:71\u201384.","journal-title":"J Pathol"},{"key":"3544_CR27","doi-asserted-by":"publisher","first-page":"105163","DOI":"10.1016\/j.ebiom.2024.105163","volume":"104","author":"K Hodgson","year":"2024","unstructured":"Hodgson K, Orozco-Moreno M, Goode EA, Fisher M, Garnham R, Beatson R, et al. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. EBioMedicine. 2024;104:105163.","journal-title":"EBioMedicine"},{"key":"3544_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s42003-024-05924-0","volume":"7","author":"R Garnham","year":"2024","unstructured":"Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, et al. ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. Commun Biol. 2024;7:276.","journal-title":"Commun Biol"},{"key":"3544_CR29","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/glycob\/cwad085","volume":"33","author":"M Orozco-Moreno","year":"2023","unstructured":"Orozco-Moreno M, Visser EA, Hodgson K, Hipgrave Ederveen AL, Bastian K, Goode EA, et al. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. Glycobiology. 2023;33:1155\u201371.","journal-title":"Glycobiology"},{"key":"3544_CR30","doi-asserted-by":"publisher","first-page":"e106255","DOI":"10.1371\/journal.pone.0106255","volume":"9","author":"TW Powers","year":"2014","unstructured":"Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, et al. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PLoS ONE. 2014;9:e106255.","journal-title":"PLoS ONE"},{"key":"3544_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00363-2","volume":"7","author":"W Butler","year":"2023","unstructured":"Butler W, McDowell C, Yang Q, He Y, Zhao Y, Hauck JS, et al. Rewiring of the N-Glycome with prostate cancer progression and therapy resistance. NPJ Precis Oncol. 2023;7:22.","journal-title":"NPJ Precis Oncol"},{"key":"3544_CR32","first-page":"1","volume":"161","author":"J Hartig","year":"2024","unstructured":"Hartig J, Young L, Grimsley G, Mehta AS, Ippolito JE, Leach RJ, et al. The glycosylation landscape of prostate cancer tissues and biofluids. Adv Cancer Res. 2024;161:1\u201330.","journal-title":"Adv Cancer Res"},{"key":"3544_CR33","doi-asserted-by":"crossref","unstructured":"Wen RM, Stark JC, Marti GEW, Fan Z, Lyu A, Garcia Marques FJ, et al. Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer. J Clin Invest. 2024;134:e180282.","DOI":"10.1172\/JCI180282"},{"key":"3544_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj1270","volume":"14","author":"MA Stanczak","year":"2022","unstructured":"Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, Sanin DE, Jacob F, Coelho R, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci Transl Med. 2022;14:eabj1270.","journal-title":"Sci Transl Med"},{"key":"3544_CR35","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","volume":"16","author":"MA Gray","year":"2020","unstructured":"Gray MA, Stanczak MA, Mantuano NR, Xiao H, Pijnenborg J, Malaker SA, et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol. 2020;16:1376\u201384.","journal-title":"Nat Chem Biol"},{"key":"3544_CR36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1021\/acscentsci.5c00510","volume":"11","author":"BM Garabedian","year":"2025","unstructured":"Garabedian BM, Bashian EE, Wang X, Thompson AJ, Paulson JC. Targeting sialidase to PD1 enhances T cell function and tumor control. ACS Cent Sci. 2025;11:1417\u201327.","journal-title":"ACS Cent Sci"},{"key":"3544_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300366120","volume":"120","author":"J Wu","year":"2023","unstructured":"Wu J, Wang X, Huang Y, Zhang Y, Su S, Shou H, et al. Targeted glycan degradation potentiates cellular immunotherapy for solid tumors. Proc Natl Acad Sci USA. 2023;120:e2300366120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3544_CR38","unstructured":"Peng L, Petrone A, Xu L, Shoemaker A. Multimeric proteins for detecting a carbohydrate and\/or treating a siglec-mediated disorder. Google Patents, 2021."},{"key":"3544_CR39","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41388-023-02604-x","volume":"42","author":"E Scott","year":"2023","unstructured":"Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, et al. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene. 2023;42:926\u201337.","journal-title":"Oncogene"},{"key":"3544_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70959","volume":"14","author":"K Bastian","year":"2025","unstructured":"Bastian K, Orozco-Moreno M, Thomas H, Hodgson K, Visser EA, Rossing E, et al. FUT8 is a critical driver of prostate tumour growth and can be targeted using fucosylation inhibitors. Cancer Med. 2025;14:e70959.","journal-title":"Cancer Med"},{"key":"3544_CR41","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1158\/1055-9965.EPI-21-0600","volume":"31","author":"V Ouellet","year":"2022","unstructured":"Ouellet V, Erickson A, UTMAs Contributing I, Wiley K, Morrissey C, Berge V, et al. The Movember Global Action Plan 1 (GAP1): unique prostate cancer tissue microarray resource. Cancer Epidemiol Biomark Prev. 2022;31:715\u201327.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3544_CR42","doi-asserted-by":"crossref","unstructured":"Joshi R, Zhou M, Lin JH, Song F, Fein D, Morrissey C, et al. A novel bispecific integrin \u03b15\u03b21\/\u03b1v antibody reprograms the Myc-regulated basal phenotype of prostate cancer with natural killer cell-mediated tumor elimination. Mol Cancer Res. 2025;23:873\u201388.","DOI":"10.1158\/1541-7786.MCR-25-0104"},{"key":"3544_CR43","doi-asserted-by":"crossref","unstructured":"Wang YT, Hsiao WY, Pham TV, Huang BR, Yeh SD, Hsu EC, et al. An enzymatic-independent function of palmitoyl hydrolase in cohesin loading onto chromosome. Nucleic Acids Res. 2025;53:gkaf257.","DOI":"10.1093\/nar\/gkaf257"},{"key":"3544_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2559.2006.02412.x","volume":"48","author":"T Kirkegaard","year":"2006","unstructured":"Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology. 2006;48:787\u201394.","journal-title":"Histopathology"},{"key":"3544_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05489-5","volume":"7","author":"J Munkley","year":"2017","unstructured":"Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, Mccullagh P, et al. The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Sci Rep. 2017;7:5249.","journal-title":"Sci Rep"},{"key":"3544_CR46","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021;39:1464\u20131478.e1468.","journal-title":"Cancer Cell"},{"key":"3544_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"},{"key":"3544_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43019-8","volume":"13","author":"K Hodgson","year":"2023","unstructured":"Hodgson K, Orozco-Moreno M, Scott E, Garnham R, Livermore K, Thomas H, et al. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer. Sci Rep. 2023;13:17031.","journal-title":"Sci Rep"},{"key":"3544_CR49","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/pros.21010","volume":"69","author":"CA Power","year":"2009","unstructured":"Power CA, Pwint H, Chan J, Cho J, Yu Y, Walsh W, et al. A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate. 2009;69:1613\u201323.","journal-title":"Prostate"},{"key":"3544_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05366-3","volume":"9","author":"T Kuchimaru","year":"2018","unstructured":"Kuchimaru T, Kataoka N, Nakagawa K, Isozaki T, Miyabara H, Minegishi M, et al. A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nat Commun. 2018;9:2981.","journal-title":"Nat Commun"},{"key":"3544_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18907-6","volume":"11","author":"E Rodrigues","year":"2020","unstructured":"Rodrigues E, Jung J, Park H, Loo C, Soukhtehzari S, Kitova EN, et al. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. Nat Commun. 2020;11:5091.","journal-title":"Nat Commun"},{"key":"3544_CR52","first-page":"97","volume":"366","author":"S Hinderlich","year":"2015","unstructured":"Hinderlich S, Weidemann W, Yardeni T, Horstkorte R, Huizing M. UDP-GlcNAc 2-epimerase\/ManNAc Kinase (GNE): a master regulator of sialic acid synthesis. Top Curr Chem 2015. 2015;366:97\u2013137.","journal-title":"Top Curr Chem 2015"},{"key":"3544_CR53","doi-asserted-by":"crossref","unstructured":"Peng L, Cao L, Shelke S, Turner A, Che J, Siddiquee Z, et al. Engineered human sialidase as a novel cancer therapeutic targeting immune-suppressive sialoglycans in tumors. Research Square 2025.","DOI":"10.21203\/rs.3.rs-6667049\/v1"},{"key":"3544_CR54","first-page":"1","volume":"34","author":"L Yang","year":"2020","unstructured":"Yang L, Wu S-C, Meng L, Gerner-Smidt C, Woods RJ. Engineered high-specificity affinity reagents for the detection of glycan sialylation. FASEB J. 2020;34:1\u20131.","journal-title":"FASEB J"},{"key":"3544_CR55","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1021\/acschembio.1c00689","volume":"17","author":"D Bojar","year":"2022","unstructured":"Bojar D, Meche L, Meng G, Eng W, Smith DF, Cummings RD, et al. A useful guide to lectin binding: machine-learning directed annotation of 57 unique lectin specificities. ACS Chem Biol. 2022;17:2993\u20133012.","journal-title":"ACS Chem Biol"},{"key":"3544_CR56","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nri3737","volume":"14","author":"MS Macauley","year":"2014","unstructured":"Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14:653\u201366.","journal-title":"Nat Rev Immunol"},{"key":"3544_CR57","first-page":"363","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363\u201385.","journal-title":"CA Cancer J Clin"},{"key":"3544_CR58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/bs.acr.2014.12.001","volume":"126","author":"RR Drake","year":"2015","unstructured":"Drake RR, Jones EE, Powers TW, Nyalwidhe JO. Altered glycosylation in prostate cancer. Adv Cancer Res. 2015;126:345\u201382.","journal-title":"Adv Cancer Res"},{"key":"3544_CR59","doi-asserted-by":"crossref","unstructured":"Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int J Mol Sci. 2019;20:1389.","DOI":"10.3390\/ijms20061389"},{"key":"3544_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.euo.2018.09.014","volume":"2","author":"JC Zarif","year":"2019","unstructured":"Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, et al. Mannose receptor-positive macrophage infiltration correlates with prostate cancer onset and metastatic castration-resistant disease. Eur Urol Oncol. 2019;2:429\u201336.","journal-title":"Eur Urol Oncol"},{"key":"3544_CR61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402903121","volume":"121","author":"G Yu","year":"2024","unstructured":"Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, et al. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci USA. 2024;121:e2402903121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3544_CR62","doi-asserted-by":"publisher","first-page":"83261","DOI":"10.18632\/oncotarget.18743","volume":"8","author":"J Cao","year":"2017","unstructured":"Cao J, Liu J, Xu R, Zhu X, Zhao X, Qian BZ. Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:83261\u20139.","journal-title":"Oncotarget"},{"key":"3544_CR63","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2021.09.004","volume":"39","author":"C Palena","year":"2021","unstructured":"Palena C, Gulley JL. A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. Cancer Cell. 2021;39:1450\u20132.","journal-title":"Cancer Cell"},{"key":"3544_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nchembio.1388","volume":"10","author":"JE Hudak","year":"2014","unstructured":"Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014;10:69\u201375.","journal-title":"Nat Chem Biol"},{"key":"3544_CR65","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, D\u00e9moulins T, et al. Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014;124:1810\u201320.","journal-title":"J Clin Invest"},{"key":"3544_CR66","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41391-024-00797-0","volume":"28","author":"NA Zorko","year":"2025","unstructured":"Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, et al. Natural killer cell infiltration in prostate cancers predict improved patient outcomes. Prostate Cancer Prostatic Dis. 2025;28:129\u201337.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3544_CR67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1615\/CritRevImmunol.2021037614","volume":"41","author":"J Wu","year":"2021","unstructured":"Wu J. Could harnessing natural killer cell activity be a promising therapy for prostate cancer? Crit Rev Immunol. 2021;41:101\u20136.","journal-title":"Crit Rev Immunol"},{"key":"3544_CR68","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395\u2013405.","journal-title":"J Clin Oncol"},{"key":"3544_CR69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu EY, Kolinsky MP, Berry WR, Retz M, Mourey L, Piulats JM, et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study. Eur Urol. 2022;82:22\u201330.","journal-title":"Eur Urol"},{"key":"3544_CR70","doi-asserted-by":"crossref","unstructured":"Bansal D, Reimers MA, Knoche EM, Pachynski RK. Immunotherapy and Immunotherapy combinations in metastatic castration-resistant prostate cancer. Cancers. 2021;13:334.","DOI":"10.3390\/cancers13020334"},{"key":"3544_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.euo.2023.10.008","volume":"7","author":"EY Yu","year":"2024","unstructured":"Yu EY, Berry WR, Gurney H, Retz M, Conter HJ, Laguerre B, et al. Pembrolizumab and enzalutamide in patients with abiraterone acetate-pretreated metastatic castration-resistant prostate cancer: cohort C of the phase 1b\/2 KEYNOTE-365 study. Eur Urol Oncol. 2024;7:509\u201318.","journal-title":"Eur Urol Oncol"},{"key":"3544_CR72","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41391-024-00865-5","volume":"28","author":"JN Graff","year":"2025","unstructured":"Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, et al. Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. Prostate Cancer Prostatic Dis. 2025;28:411\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3544_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101285","volume":"83","author":"RE Farrell","year":"2025","unstructured":"Farrell RE, Stelzer KA, Liu GJ, Skropeta D. Emerging role of sialylation in cancer therapy resistance: Mechanisms and therapeutic implications. Drug Resist Updat. 2025;83:101285.","journal-title":"Drug Resist Updat"},{"key":"3544_CR74","doi-asserted-by":"crossref","unstructured":"Goode EA, Orozco-Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z, et al. Sialylation inhibition can partially revert acquired resistance to enzalutamide in prostate cancer cells. Cancers. 2024;16:2953.","DOI":"10.3390\/cancers16172953"},{"key":"3544_CR75","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-24-0060","volume":"30","author":"MC Dallos","year":"2024","unstructured":"Dallos MC, Obradovic AZ, McCann P, Chowdhury N, Pratapa A, Aggen DH, et al. Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer. Clin Cancer Res. 2024;30:5218\u201330.","journal-title":"Clin Cancer Res"},{"key":"3544_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02973-1","volume":"11","author":"X Long","year":"2020","unstructured":"Long X, Hou H, Wang X, Liu S, Diao T, Lai S, et al. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration. Cell Death Dis. 2020;11:779.","journal-title":"Cell Death Dis"},{"key":"3544_CR77","doi-asserted-by":"publisher","first-page":"CT034","DOI":"10.1158\/1538-7445.AM2023-CT034","volume":"83","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Johnson M, Tolcher A, Chen CT, Dai T, Curti BD, et al. Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors. Cancer Res. 2023;83:CT034.","journal-title":"Cancer Res"},{"key":"3544_CR78","first-page":"A862","volume":"12","author":"MR Sharma","year":"2024","unstructured":"Sharma MR, Johnson ML, Puzanov I, Sznol M, Mckean M, Gainor JF, et al. 758 GLIMMER-01: phase 1\/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. J Immunother Cancer. 2024;12:A862.","journal-title":"J Immunother Cancer"},{"key":"3544_CR79","doi-asserted-by":"publisher","first-page":"10304","DOI":"10.1073\/pnas.1608069113","volume":"113","author":"H Xiao","year":"2016","unstructured":"Xiao H, Woods EC, Vukojicic P, Bertozzi CR. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Natl Acad Sci USA. 2016;113:10304\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3544_CR80","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1158\/1538-7445.AM2026-7158","volume":"86","author":"W Gatlin","year":"2026","unstructured":"Gatlin W, Chang JK, Cao L, Xu H, Metha H, Timins M, et al. Abstract 7158: Human sialidase-armed anti-B7-H3 antibody that enhances innate and adaptive antitumor immune responses. Cancer Res. 2026;86:7158.","journal-title":"Cancer Res"},{"key":"3544_CR81","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al. B7-H3 as a Therapeutic target in advanced prostate cancer. Eur Urol. 2023;83:224\u201338.","journal-title":"Eur Urol"},{"key":"3544_CR82","doi-asserted-by":"publisher","first-page":"e0241934","DOI":"10.1371\/journal.pone.0241934","volume":"16","author":"I Vidal","year":"2021","unstructured":"Vidal I, Zheng Q, Hicks JL, Chen J, Platz EA, Trock BJ, et al. GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. PLoS ONE. 2021;16:e0241934.","journal-title":"PLoS ONE"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03544-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:02:34Z","timestamp":1789477354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03544-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,5]]}},"alternative-id":["3544"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03544-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MK, LC, WG, and LP are employees and hold stock in Palleon Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The prostate cancer tissue samples analysed in Fig.\u00a0\n                      \n                      , Fig.\u00a0\n                      \n                      and Fig.\u00a0\n                      \n                      were kindly provided by the Prostate Cancer Biorepository Network (PCBN). Written informed consent was obtained from all patients. The PCBN ethics committee reviewed our project and provided ethical approval for use of the samples in our project (refs: 191112.1, 210412.1 and 210203.1). All animal models complied with the UK Animals (Scientific Procedures) Act 1986 and were reviewed and approved by the local Research Ethics Committees of the University of Sheffield under Home Office project licence (PP3267943). The animal research performed in this study is reported in accordance with ARRIVE guidelines. Leucocyte cones were ordered from the National Health Service Blood and Transplant Service (NHSBTS) (The NHSBTS obtains informed consent from the donors and has internal ethical approval under the terms of HTA licence).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}